
Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.
Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot is an episode from FierceBiotech Radio. Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the...
This episode belongs to FierceBiotech Radio.
Use the player on this page to stream the episode online.
Published Oct 8, 2015, 26:30 long, audio available.
Fierce editors discuss another rough week for biotech stocks, Valeant Pharmaceuticals' doggedness in the face of congressional inquiry, and a curious new trend in pharma advertising.
You can listen to Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot online on Radio and Podcast. Open the player on this page to stream the available audio.
Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot is an episode from FierceBiotech Radio.
This episode is 26:30 long.
This episode was published on Oct 8, 2015.
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Yes. This page shows related episodes from FierceBiotech Radio when more episodes are available from the podcast feed.
You can listen to Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot on this page when the episode audio is available from the podcast feed.
Biotech's Wall Street malaise, Valeant's Washington woes, and immuno-oncology's primetime slot is from FierceBiotech Radio.
Published Oct 8, 2015 and 26:30 long